An obesity medication is reportedly poised to shatter the record for pharmaceutical sales volume 

A prescription drug that combats obesity is expected to become the biggest-grossing pharmaceutical in history, ringing up five times the sales volume of its nearest competitor, an industry authority predicts. 

“With modest patient penetration, we could see tirzepatide generating more than $100 billion in sales annually” for drug manufacturer Eli Lilly & Co. (LLY), says Bank of America analyst Geoffery Meacham. 

That would dwarf the one-year record of $21 billion in sales that the anti-inflammatory drug Humira posted in 2021 for its maker, AbbVie (ABBV). But a tirzepatide juggernaut seems likely, partly because the medication could...

Subscribe or sign in to view the rest of this content

All digital content on this site is FREE!

Sign In